XORTX Therapeutics Inc. announced that the departure of Jacqueline Le Saux who decided to not stand for re-election. The Board extends its appreciation to Jacqueline for her 2+ years of service to XORTX. Jacquelineâs expertise in governance and contribution to both the audit committee and notably, the corporate governance and nominating committee of the Board was significant as the Company transitioned during her tenure as a director from being listed on the CSE to the TSX Venture Exchange and Nasdaq Capital Market.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.5 CAD | -11.17% | +4.48% | +20.69% |
17/05 | XORTX Therapeutics Reprices Warrants Connected With U.S. IPO | MT |
17/05 | XORTX Therapeutics Brief: Says Repriced Balance of Warrants Issued in Connection with October 2021 US IPO | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+20.69% | 7.43M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- XRTX Stock
- News XORTX Therapeutics Inc.
- XORTX Therapeutics Inc. Announces Departure of Jacqueline Le Saux